GSK Investigational Site
Toronto, Ontario, M1L 4S4, Canada
NCT Number: NCT00488098
The study is to show the new salt formulation of GSK372475 is equivalent to the old salt formulation of GSK372475.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Toronto, Ontario, M1L 4S4, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at predose, 0.5,1-24, 36,48,60,72,96 and 1-4 weeks post dose.
Time frame: all visits
Time frame: at screening,Day-1, predose, 1,6,24,48,72 and week 2 post dose.
Time frame: at screening and 2 weeks post dose
GlaxoSmithKline
Industry
An Open Label, Randomized, Parallel Groups, Bioequivalence Study to Compare a Single Oral Dose of GSK372475B or GSK372475C in Male and Female Healthy Volunteers.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00435695
Anxiety Disorders, Depressive Disorder
Toronto, Ontario, Canada
View Trial DetailsNCT07470125
Healthy Subjects
Seoul, South Korea
View Trial DetailsNCT06818032
Healthy, Healthy Adult
Burlington, Vermont, United States
View Trial DetailsNCT00761631
Healthy Subjects
Benton, Arkansas, United States
View Trial Details